Rapt Therapeutics Unveils Pipeline Progress for Ozureprubart in Allergic Diseases
I'm PortAI, I can summarize articles.
Rapt Therapeutics Inc. has updated its clinical development programs for inflammatory diseases, focusing on Ozureprubart (RPT904), a next-generation anti-IgE antibody for food allergies and chronic spontaneous urticaria (CSU). The drug aims for less frequent dosing to enhance patient compliance. Positive Phase 2 data in CSU show 16-week durability. A Phase 2b trial for food allergy is underway, with results expected in early 2027. Rapt holds ex-China rights, while Jemincare has rights in China and nearby regions. The company is also advancing its oncology and inflammatory disease pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments